TODAY'S MARKET INTELLIGENCE
Lukang Pharmaceutical's subsidiary gets supplementary approval for Crisaborole Ointment as MAH
English summary
Lukang Pharmaceutical announced that its subsidiary Saite received NMPA approval to become the marketing authorization holder of Crisaborole Ointment, replacing Zhejiang Saimei Pharma. Cumulative investment in the project is about RMB 7.66 million.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence